$JRSS
JRSIS HEALTH CARE Corp

2022 Q4 Form 10-Q Financial Statement

#000121390022071540 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $89.17K $12.16M
YoY Change -99.32% 21.39%
Cost Of Revenue $2.744M
YoY Change 52.62%
Gross Profit $9.415M
YoY Change 14.56%
Gross Profit Margin 77.43%
Selling, General & Admin $127.5K $125.4K $3.667M
YoY Change -96.35% -96.58% 68.88%
% of Gross Profit 38.94%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.130K $2.166K $837.9K
YoY Change -99.75% -99.74% 28.96%
% of Gross Profit 8.9%
Operating Expenses $133.0K $132.5K $8.336M
YoY Change -98.52% -98.41% 38.36%
Operating Profit -$132.5K $1.079M
YoY Change -112.28% -50.81%
Interest Expense -$344.5K
YoY Change 8.44%
% of Operating Profit -31.93%
Other Income/Expense, Net -$1.740K -$720.00
YoY Change -100.57% -87.19%
Pretax Income -$45.56K -$132.5K $733.7K
YoY Change -102.97% -118.05% -60.77%
Income Tax $0.00 $192.2K
% Of Pretax Income 26.2%
Net Earnings -$45.56K -$132.5K $368.5K
YoY Change -105.24% -135.94% -51.89%
Net Earnings / Revenue -51.09% 3.03%
Basic Earnings Per Share $0.00 $0.03
Diluted Earnings Per Share $0.00 $0.00 $19.56K
COMMON SHARES
Basic Shares Outstanding 58.37M shares 58.37M shares 18.63M shares
Diluted Shares Outstanding 58.37M shares 18.84M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.62K $11.08K $527.6K
YoY Change -93.15% -97.9% -35.03%
Cash & Equivalents $58.62K $11.08K $527.6K
Short-Term Investments
Other Short-Term Assets $736.4K $818.2K $2.395M
YoY Change -77.5% -65.84% 96.32%
Inventory $562.0K $1.745M
Prepaid Expenses
Receivables $7.418M
Other Receivables $2.987K $3.037K $68.57K
Total Short-Term Assets $798.9K $832.3K $12.15M
YoY Change -94.24% -93.15% 88.6%
LONG-TERM ASSETS
Property, Plant & Equipment $38.99K $39.94K $55.69M
YoY Change -99.93% -99.93% 28.37%
Goodwill
YoY Change
Intangibles $303.2K
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.153M
YoY Change -1.19%
Total Long-Term Assets $57.13K $61.49K $58.84M
YoY Change -99.91% -99.9% 26.35%
TOTAL ASSETS
Total Short-Term Assets $798.9K $832.3K $12.15M
Total Long-Term Assets $57.13K $61.49K $58.84M
Total Assets $856.0K $893.8K $71.00M
YoY Change -98.87% -98.74% 33.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $24.71K $8.000K $10.81M
YoY Change -99.8% -99.93% 84.91%
Accrued Expenses $18.52K $17.53K $2.183M
YoY Change -99.01% -99.2% 259.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $280.3K
YoY Change -100.0% -100.0% -46.96%
Long-Term Debt Due $49.71K $2.287M
YoY Change -97.33% 39.83%
Total Short-Term Liabilities $43.23K $27.53K $17.70M
YoY Change -99.75% -99.84% 88.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $15.35M
YoY Change -100.0% -100.0% 2.48%
Other Long-Term Liabilities $1.430K $5.520K $2.693M
YoY Change -99.97% -99.79% 1851.58%
Total Long-Term Liabilities $1.430K $5.520K $18.04M
YoY Change -99.99% -99.97% 19.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.23K $27.53K $17.70M
Total Long-Term Liabilities $1.430K $5.520K $18.04M
Total Liabilities $44.66K $33.05K $50.17M
YoY Change -99.92% -99.93% 38.26%
SHAREHOLDERS EQUITY
Retained Earnings -$23.71M -$23.66M
YoY Change 1162.76%
Common Stock $58.37K $58.37K
YoY Change 213.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $811.3K $860.8K $20.83M
YoY Change
Total Liabilities & Shareholders Equity $856.0K $893.8K $71.00M
YoY Change -98.87% -98.74% 33.91%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$45.56K -$132.5K $368.5K
YoY Change -105.24% -135.94% -51.89%
Depreciation, Depletion And Amortization $2.130K $2.166K $837.9K
YoY Change -99.75% -99.74% 28.96%
Cash From Operating Activities $67.33K $867.3K $3.759M
YoY Change -92.12% -76.93% -12.91%
INVESTING ACTIVITIES
Capital Expenditures -$1.730K -$1.850K -$2.814M
YoY Change -100.15% -99.93% -20.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$1.534M
YoY Change -100.0% -100.0% 40.6%
Cash From Investing Activities $1.720K -$1.850K -$4.348M
YoY Change -99.82% -99.96% -6.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -900.0K 745.0K
YoY Change -100.0% -220.82% -196.03%
NET CHANGE
Cash From Operating Activities 67.33K 867.3K 3.759M
Cash From Investing Activities 1.720K -1.850K -4.348M
Cash From Financing Activities 0.000 -900.0K 745.0K
Net Change In Cash 69.05K -34.59K 156.2K
YoY Change -73.5% -122.14% -114.38%
FREE CASH FLOW
Cash From Operating Activities $67.33K $867.3K $3.759M
Capital Expenditures -$1.730K -$1.850K -$2.814M
Free Cash Flow $69.06K $869.2K $6.573M
YoY Change -121.92% -86.78% -16.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
528458
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56013
dei Entity Registrant Name
EntityRegistrantName
JRSIS HEALTH CARE CORPORATION.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4562047
dei Entity Address Address Line1
EntityAddressAddressLine1
3/F Building A
dei Entity Address Address Line2
EntityAddressAddressLine2
De Run YuanNo. 19 Chang Yi Road
dei Entity Address Address Line3
EntityAddressAddressLine3
Chang Yi Road, Chang Ming ShuiWu Gui Shan
dei Entity Address City Or Town
EntityAddressCityOrTown
Zhong Shan City
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58366569 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11084 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29847 usd
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3037 usd
CY2022Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
818215 usd
CY2021Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
13836084 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
832336 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
13865931 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39937 usd
CY2022Q3 jrss Right Of Use Asset Net Noncurrent
RightOfUseAssetNetNoncurrent
21555 usd
CY2021Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
61826821 usd
CY2022Q3 us-gaap Assets
Assets
893828 usd
CY2021Q4 us-gaap Assets
Assets
75692752 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
66000 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2001 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1456919 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1493 usd
CY2022Q3 jrss Capital Lease Obligations Current Portion
CapitalLeaseObligationsCurrentPortion
16034 usd
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
16076570 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
27528 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17599502 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
7 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
5521 usd
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
24991063 usd
CY2022Q3 us-gaap Liabilities
Liabilities
33049 usd
CY2021Q4 us-gaap Liabilities
Liabilities
42590572 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58366569 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58366569 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18628569 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18628569 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
58366 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
18628 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24452501 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23381121 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23660185 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1877296 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10097 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
545449 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
860779 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22067902 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
11034278 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
860779 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33102180 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
893828 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75692752 usd
CY2022Q3 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
4861 usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
9282 usd
CY2022Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
81821 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
163643 usd
CY2022Q3 us-gaap Supplies Expense
SuppliesExpense
4927 usd
CY2021Q3 us-gaap Supplies Expense
SuppliesExpense
992 usd
us-gaap Supplies Expense
SuppliesExpense
34195 usd
us-gaap Supplies Expense
SuppliesExpense
6184 usd
CY2022Q3 jrss Rentals And Leases
RentalsAndLeases
4323 usd
jrss Rentals And Leases
RentalsAndLeases
10435 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
34362 usd
CY2021Q3 us-gaap Professional Fees
ProfessionalFees
11556 usd
us-gaap Professional Fees
ProfessionalFees
60850 usd
us-gaap Professional Fees
ProfessionalFees
31701 usd
CY2021Q3 jrss Warrant Expense
WarrantExpense
-5077 usd
jrss Warrant Expense
WarrantExpense
-7 usd
jrss Warrant Expense
WarrantExpense
1636 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2166 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3671 usd
CY2022Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
132460 usd
CY2021Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7471 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
282069 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
39521 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-132460 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7471 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-282069 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-39521 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-132460 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7471 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-282069 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39521 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-132460 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-7471 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-282069 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-39521 usd
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
548966 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
2100025 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-132460 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
541495 usd
us-gaap Profit Loss
ProfitLoss
-33675739 usd
us-gaap Profit Loss
ProfitLoss
2060504 usd
CY2022Q3 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-3741 usd
CY2021Q3 jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-7257 usd
jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-21298 usd
jrss Foreign Currency Translation Adjustment From Continued Operations
ForeignCurrencyTranslationAdjustmentFromContinuedOperations
-52129 usd
CY2021Q3 jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-98 usd
jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-301922 usd
jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
-353332 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-128719 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
548850 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33352519 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
2465965 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0023
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0004
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.007
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.0021
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0023
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0004
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.007
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.0021
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.0295
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.8228
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.1142
CY2021Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.0291
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.8228
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.1129
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.0023
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.0291
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8298
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.112
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.0023
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.0287
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8298
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.1108
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58366569 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18628569 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40583562 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18393563 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58366569 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18838569 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40583562 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18603563 shares
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28840425 usd
CY2021Q1 us-gaap Profit Loss
ProfitLoss
495922 usd
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-73749 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29262598 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
1023087 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
141428 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
471855 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
30898968 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
541495 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7355 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31447818 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33102180 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
2638816 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
208210 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35949206 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-34984724 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-127290 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1056510 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
60000 usd
CY2022Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-970560 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6356 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
989498 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-132460 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3741 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
860779 usd
us-gaap Profit Loss
ProfitLoss
-33675739 usd
us-gaap Profit Loss
ProfitLoss
2060504 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33393670 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
2100025 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-282069 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-39521 usd
us-gaap Depreciation
Depreciation
3671 usd
jrss Warrant Expenses
WarrantExpenses
-7 usd
jrss Warrant Expenses
WarrantExpenses
1636 usd
us-gaap Share Based Compensation
ShareBasedCompensation
163643 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3037 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-62000 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
2001 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
99739 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1493 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-172305 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-146 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
3171627 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
7378627 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2999322 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7378481 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46367 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-46367 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-2783041 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-6444421 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2829408 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6444421 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
69260 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60000 usd
jrss Derivative Financial Instrument
DerivativeFinancialInstrument
-7 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
129267 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-867508 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-1260015 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-738241 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1260015 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-276560 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8770 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-844887 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-317185 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
855971 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
844827 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11084 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
527642 usd
CY2022Q3 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
11084 usd
CY2021Q3 us-gaap Disposal Group Including Discontinued Operation Cash And Cash Equivalents
DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
30905 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
496737 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
11084 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
527642 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
13086 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
25194 usd
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
406544 usd
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
1076691 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1056510 usd
us-gaap Stock Issued1
StockIssued1
970560 usd
CY2022Q2 jrss Equity Method Investment Ownership Percent
EquityMethodInvestmentOwnershipPercent
0.70 pure
CY2022Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
5392000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>C. Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>E. Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the nine months ended September 30, 2022 and 2021, no customer accounted for more than 10% of net revenue. As of September 30, 2022 and December 31, 2021, no customer accounted for more than 5% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
jrss Summary Of Changes In Warrant Liability Table Textblock
SummaryOfChangesInWarrantLiabilityTableTextblock
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">Balance at January 1, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Balance at September 30, 2022 (Unaudited)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022Q2 jrss Negotiated Value
NegotiatedValue
1056510 usd
CY2022Q2 us-gaap Other Expenses
OtherExpenses
981858 usd
CY2022Q2 jrss Expense Term Year
ExpenseTermYear
P3Y
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
81821 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
163643 usd
us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.25 pure
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>O. Reclassification</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The comparative figures before April 1, 2022 have been reclassified to conform to current year presentation to reflect the disposal of a component of business derived from the recognition of a spin-off transaction on April 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
5392000 shares
us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.70 pure
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
43370 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3433 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
39937 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2166 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3671 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1528 usd
CY2022Q1 jrss Lease Payment Term
LeasePaymentTerm
P23M
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21555 usd
CY2022Q3 jrss Total Lease Assets
TotalLeaseAssets
21555 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16034 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5521 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
21555 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3935 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16231 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1389 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
21555 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
4323 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
352600 usd
CY2021Q3 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
352600 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
10435 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
902327 usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
902327 usd
jrss Lease Asset
LeaseAsset
30552 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
8997 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21555 usd
CY2022Q3 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
2001 usd
CY2021Q4 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
1456919 usd
CY2022Q1 jrss Owned Percentage
OwnedPercentage
1 pure
CY2022Q2 us-gaap Shares Issued
SharesIssued
39130000 shares
CY2022Q2 jrss Acquired Shares
AcquiredShares
8000000 shares
CY2022Q2 jrss Owned Shares
OwnedShares
47130000 shares
CY2022Q2 jrss Common Stock Percentage
CommonStockPercentage
0.807 pure
CY2022Q1 jrss Total Share Issued
TotalShareIssued
6000000 shares
CY2022Q1 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
60000 usd
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.01
CY2022Q2 jrss Transfer Agreement Description
TransferAgreementDescription
Runteng entered into an agreement regarding a transfer of Jiarun’s equity with Zhang Junsheng. Pursuant to the transfer agreement, Runteng transferred to Mr. Zhang equity interest in Jiarun, representing 70% of equity interest in Jiarun and Mr. Zhang transferred to Runteng 5,392,000 shares of the Company’s common stock. On May 27, 2022, the Company cancelled the respecrtive 5,392,000 shares of the Company’s common stock. Since this transaction required certain authoritative approval before effective, the publication of these transactions were delay so as to obtain all parties consent and advance authoritative approval. As of May 27, 2022, the issued and outstanding share number of the Company was 58,366,569, the balance of the number of shares held by Mr. Zhang and Mr. Zhong were nil (0%) and 4,7130,000 (80.7%), respectively.
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58366569 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58366569 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18628569 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18628569 shares
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
dei City Area Code
CityAreaCode
+86-760
dei Local Phone Number
LocalPhoneNumber
88963658
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
usd
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
usd
CY2022Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2021Q4 jrss Right Of Use Asset Net Noncurrent
RightOfUseAssetNetNoncurrent
usd
CY2022Q3 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
usd
CY2022Q3 us-gaap Revenues
Revenues
usd
CY2021Q3 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
usd
CY2021Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
usd
CY2021Q3 jrss Rentals And Leases
RentalsAndLeases
usd
jrss Rentals And Leases
RentalsAndLeases
usd
CY2022Q3 jrss Warrant Expense
WarrantExpense
usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2022Q3 jrss Foreign Currency Translation Adjustment From Discontinued Operations
ForeignCurrencyTranslationAdjustmentFromDiscontinuedOperations
usd
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
jrss Derivative Financial Instrument
DerivativeFinancialInstrument
usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Expense
InterestExpense
usd
us-gaap Interest Expense
InterestExpense
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
us-gaap Stock Issued1
StockIssued1
usd
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
usd
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
usd
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
usd
CY2022Q3 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
usd
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
usd
us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Address Country
EntityAddressCountry
CN
dei Entity Central Index Key
EntityCentralIndexKey
0001597892

Files In Submission

Name View Source Status
0001213900-22-071540-index-headers.html Edgar Link pending
0001213900-22-071540-index.html Edgar Link pending
0001213900-22-071540.txt Edgar Link pending
0001213900-22-071540-xbrl.zip Edgar Link pending
f10q0922ex31-1_jrsishealth.htm Edgar Link pending
f10q0922ex31-2_jrsishealth.htm Edgar Link pending
f10q0922ex32-1_jrsishealth.htm Edgar Link pending
f10q0922ex32-2_jrsishealth.htm Edgar Link pending
f10q0922_jrsishealth.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jrss-20220930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
jrss-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
jrss-20220930_pre.xml Edgar Link unprocessable
jrss-20220930_lab.xml Edgar Link unprocessable
f10q0922_jrsishealth_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
jrss-20220930_cal.xml Edgar Link unprocessable